



RADIANT 4 - Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)

22/11/2024 03:45:34

Main Information

Primary registry identifying number

LBCTR2020011379

Protocol number

CRAD001T2302

MOH registration number

ص/262

Study registered at the country of origin

Yes

Study registered at the country of origin: Specify

Type of registration

Retrospective

Type of registration: Justify

This study was submitted prior to LBCTR initiation

Date of registration in national regulatory agency

13/01/2015

Primary sponsor

Novartis Pharmaceuticals

Primary sponsor: Country of origin

Novartis Pharmaceuticals

Date of registration in primary registry

07/01/2020

Date of registration in national regulatory agency

13/01/2015

Public title

RADIANT 4 - Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)

Acronym

Scientific title

A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin

Acronym

Brief summary of the study: English

The purpose of this study is to compare the antitumor activity of everolimus plus best supportive care versus placebo plus best supportive care in patients with advanced nonfunctional neuroendocrine tumor of gastrointestinal or lung origin.

Brief summary of the study: Arabic

بالإضافة إلى أفضل رعاية داعمة مقابل (RAD001) إيفيروليموس Everolimus دراسة عشوائية ومتعددة المراكز في المرحلة الثالثة لدواء العلاج الإرضائي وأفضل رعاية داعمة في علاج المرضى المصابين بحالة متقدمة من أورام الغدد الصمّ العصبية يكون مصدرها معدياً معويّاً أو 4مشع-(RADIANT-4) - رثنويّاً

Health conditions/problem studied: Specify

Advanced Nonfunctional NeuroEndocrine Tumor

Interventions: Specify

•Drug: Everolimus

After randomization, patients will receive everolimus once daily until disease progression, intolerable toxicity, or consent withdrawal

Other Name: RAD001





•Drug: Everolimus Placebo

After randomization, patients will receive everolimus placebo once daily until disease progression, intolerable toxicity, or consent withdrawal

Key inclusion and exclusion criteria: Inclusion criteria

- Pathologically confirmed, well differentiated (G1 or G2), advanced (unresectable or metastatic), neuroendocrine tumor of GI or lung origin
- No history of and no active symptoms related to carcinoid syndrome
- In addition to treatment-naive patients, patients previously treated with SSA, Interferon (IFN), one prior line of chemotherapy, and/or PRRT are allowed into the study. Pretreated patients must have progressed on or after the last treatment
- Radiological documented disease progression within 6 months prior to randomization
- Measurable disease
- WHO performance status ≤ 1
- Adequate bone marrow, liver and renal function

Key inclusion and exclusion criteria: Gender

Both

Key inclusion and exclusion criteria: Specify gender

Key inclusion and exclusion criteria: Age minimum

18

Key inclusion and exclusion criteria: Age maximum

99

Key inclusion and exclusion criteria: Exclusion criteria

- Patients with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, pancreatic islet cell carcinoma, insulinoma, glucagonoma, gastrinoma, goblet cell carcinoid, large cell neuroendocrine carcinoma and small cell carcinoma
 - Patients with pancreatic NET or NET of origins other than GI or Lung
 - Patients with history of or active symptoms of carcinoid syndrome (e.g. flushing, diarrhea)
 - Patients with more than one line of prior chemotherapy
 - Prior targeted therapy
 - Hepatic locoregional therapy within the last 6 months
 - Prior therapy with mTOR inhibitors (e.g. sirolimus, temsirolimus, deforolimus)
 - Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
 - Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
 - Uncontrolled diabetes mellitus as defined by HbA1c $>8\%$ despite adequate therapy
- Patients who have any severe and/or uncontrolled medical conditions such as:
- unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6 months prior to randomization, serious uncontrolled cardiac arrhythmia
 - active or uncontrolled severe infection
 - liver disease such as cirrhosis, decompensated liver disease, and chronic hepatitis (i.e. quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA)
- Chronic treatment with corticosteroids or other immunosuppressive agents
 - Known history of HIV seropositivity
 - Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply.

Type of study

Interventional

Type of intervention

Pharmaceutical

Type of intervention: Specify type

N/A

Trial scope

Therapy

Trial scope: Specify scope

N/A

Study design: Allocation

Randomized controlled trial

Study design: Masking

Open (masking not used)

Study design: Control

Placebo

Study phase

3

Study design: Purpose

Treatment

Study design: Specify purpose

N/A

Study design: Assignment

Study design: Specify assignment



Parallel

N/A

IMP has market authorization

Yes, Lebanon and Worldwide

IMP has market authorization: Specify

Austria, Belgium, Canada, China, Colombia, Czechia, Germany, ...

Name of IMP

everolimus (RAD001)

Year of authorization

2010

Month of authorization

5

Type of IMP

Cell therapy

Pharmaceutical class

proliferation signal inhibitor in the mammalian target of rapamycin (mTOR)

Therapeutic indication

proliferation signal inhibitor in the mammalian target of rapamycin (mTOR)

Therapeutic benefit

Progression Free Survival (PFS)

Study model

N/A

Study model: Explain model

N/A

Study model: Specify model

N/A

Time perspective

N/A

Time perspective: Explain time perspective

N/A

Time perspective: Specify perspective

N/A

Target follow-up duration

Target follow-up duration: Unit

Number of groups/cohorts

Biospecimen retention

Samples without DNA

Biospecimen description

Samples are sent to central quintiles laboratories

Target sample size

5

Actual enrollment target size

5

Date of first enrollment: Type

Actual

Date of first enrollment: Date

25/09/2012

Date of study closure: Type

Date of study closure: Date



| | |
|---|--|
| Actual | 31/12/2021 |
| Recruitment status Complete | Recruitment status: Specify |
| Date of completion 17/07/2013 | |
| IPD sharing statement plan No | IPD sharing statement description Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com |
| Additional data URL https://clinicaltrials.gov/ct2/show/record/NCT01524783 | |
| Admin comments | |
| Trial status Approved | |

Secondary Identifying Numbers

| Full name of issuing authority | Secondary identifying number |
|--------------------------------|------------------------------|
| Clinical trials.gov | NCT01524783 |

Sources of Monetary or Material Support

| Name |
|--------------------------|
| Novartis Pharmaceuticals |

Secondary Sponsors

| Name |
|------|
| NA |



Contact for Public/Scientific Queries

| Contact type | Contact full name | Address | Country | Telephone | Email | Affiliation |
|--------------|-------------------|-----------|---------|--------------|-------------------------------|--|
| Public | Ali Shamseddin | Beirut | Lebanon | 03344277 | as04@aub.edu.lb | American University of Beirut Medical Center |
| Scientific | Hind Khairallah | Sin elfil | Lebanon | 01512002#271 | Hind.Khairallah@fattal.com.lb | Khalil Fattal et Fils s.a.l. |
| Public | Joseph Kattan | Beirut | Lebanon | 011424942 | jkattan62@hotmail.com | Hotel Dieu De France |

Centers/Hospitals Involved in the Study

| Center/Hospital name | Name of principles investigator | Principles investigator speciality | Ethical approval |
|--|---------------------------------|------------------------------------|------------------|
| American University of Beirut Medical Center | Ali Shamseddin | Hematology | Approved |
| Hotel Dieu De France | Joseph Kattan | Hematology | Approved |

Ethics Review

| Ethics approval obtained | Approval date | Contact name | Contact email | Contact phone |
|--|---------------|--------------|-----------------------|----------------------------|
| American University of Beirut Medical Center | 11/03/2013 | Fuad Ziyadeh | fz05@aub.edu.lb | 961 (0) 1 350 000 ext:5445 |
| Hotel Dieu de France | 07/05/2012 | Nancy Alam | nancy.alam@usj.edu.lb | 961 (0) 1 421000 ext 2335 |



Countries of Recruitment

| Name |
|--------------------------|
| Lebanon |
| Australia |
| Belgium |
| Canada |
| China |
| Colombia |
| Greece |
| Italy |
| Norway |
| Saudi Arabia |
| Turkey |
| United Arab Emirates |
| United States of America |

Health Conditions or Problems Studied

| Condition | Code | Keyword |
|----------------------|--------------------------------------|----------------------|
| Neuroendocrine tumor | Endocrine gland, unspecified (C75.9) | Neuroendocrine tumor |

Interventions

| Intervention | Description | Keyword |
|---|---|---|
| ICF, Lab tests , physical exam, radiology | ICF, Lab tests , physical exam, radiology | ICF, Lab tests , physical exam, radiology |

Primary Outcomes

| Name | Time Points | Measure |
|--|-------------|-----------|
| Progression Free Survival (PFS) Based on Central Radiology Assessment Per Kaplan-Meier | 18 months | 18 months |



Key Secondary Outcomes

| Name | Time Points | Measure |
|---|-------------|-----------|
| •Overall Survival (OS) Using Kaplan-Meier | 18 Months | 18 Months |
| •Overall Safety Evaluation of Everolimus Versus Placebo | 5 years | 5 years |

Trial Results

Summary results

Study results globally

Date of posting of results summaries

Date of first journal publication of results

Results URL link

Baseline characteristics

Participant flow

Adverse events

Outcome measures

URL to protocol files